Infertility
Conditions
Brief summary
This is a randomized-controlled trial evaluating the effect of the use of vitamin D supplementation on the live birth rate in women undergoing in vitro fertilization (IVF). The hypothesis is that administration of vitamin D can increase the live birth rate for women undergoing IVF.
Detailed description
Patients undergoing IVF treatment cycle at Queen Mary Hospital and Kwong Wah Hospital will be invited to participate in this study. Participating subjects will be randomized into either (i) vitamin D or (ii) placebo group in a 1:1 allocation ratio by computer-generated random numbers one month before IVF. Subjects allocated to the vitamin D group will take vitamin D 50,000IU per week from recruitment for 4 weeks, followed by 50,000IU once every 2 weeks throughout the IVF cycle until fetal viability is confirmed at 6 weeks (if pregnant), after which they will be switched to Materna. If not pregnant, they will continue Vitamin D 50,000IU once every 2 weeks until 6 months from randomization, during which they can undergo frozen-thawed embryo transfer. Subjects allocated to the placebo group will take placebo tablets which will be identical to the active drug. If pregnant and fetal viability is confirmed at 6 weeks, they will be switched to Materna. If not pregnant, they will continue the placebo tablets until 6 months from randomization, during which they can undergo frozen-thawed embryo transfer. The clinician and patients will both be blinded to the randomization throughout the course of treatment. The live birth rate of the two groups will be compared.
Interventions
DIETARY_SUPPLEMENTVitamin D
as above
DIETARY_SUPPLEMENTPlacebo
as above
Sponsors
Kwong Wah Hospital
The University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No
Inclusion criteria
* Infertile women undergoing IVF * Aged between 18 and 43 years old, inclusive, at the time of signing informed consent * Having given voluntary written informed consent
Exclusion criteria
* Already taking vitamin D * Undergoing preimplantation genetic testing * Use of donor oocytes or donor embryos * Presence of hydrosalpinx not corrected surgically * Active tuberculosis/ receiving therapy for tuberculosis * History of any medical condition or medications that may predispose to vitamin D sensitivity, altered vitamin D metabolism and/or hypercalcemia, including history of renal/ureteral stones, parathyroid disease, renal or liver failure, current use of anticonvulsants, current use of steroid * Allergy to vitamin D * Abnormal serum calcium values
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Live birth rate | 10 months | per embryo transfer procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum and follicular vitamin D levels | 6 weeks | vitamin D levels |
| Pregnancy rate | 8 weeks | pregnancy test positive |
| Cumulative pregnancy rate within 6 months of randomization | 6 months | within 6 months of randomization |
| Ongoing pregnancy rate | 12 weeks | Viable pregnancy beyond 8 weeks |
| Adverse events | 6 months | Number of women with adverse events |
| Clinical pregnancy rate | 10 weeks | Presence of intrauterine gestational sac on ultrasound |
Countries
Hong Kong
Contacts
Primary ContactJennifer Ka Yee Ko, MBBS
Outcome results
None listed